Evaluation of a Pharmacist-Led Intervention to Improve Statin Use in Persons with Diabetes [0.03%]
药师主导干预改善糖尿病患者的他汀使用效果评价研究
Sarah L Anderson,Joel C Marrs,Cynthia R Chachas et al.
Sarah L Anderson et al.
Background: The Statin Use in Persons with Diabetes (SUPD) measure, developed and endorsed by the Pharmacy Quality Alliance and National Quality Forum, has been adopted by the Centers for Medicare & Medicaid Services as p...
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions [0.03%]
美国身体疾病患者的私人保险中难治性抑郁的经济负担
Maryia Zhdanava,Harsh Kuvadia,Kruti Joshi et al.
Maryia Zhdanava et al.
Background: Little is known about the economic burden of treatment-resistant depression (TRD) in patients with physical conditions. Objective: ...
Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective [0.03%]
从美国医院的角度估计接受Tisagenlecleucel治疗的儿童和年轻成人复发或难治性急性淋巴细胞白血病患者的总成本
Hongbo Yang,Yanni Hao,Cynthia Z Qi et al.
Hongbo Yang et al.
Background: Tisagenlecleucel was approved for the treatment of pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) based on the pivotal ELIANA trial. ...
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease [0.03%]
阿哌沙班和伊索替康乙酯作为心血管疾病附加疗法的有效性和价值
Patricia G Synnott,R Brett McQueen,Daniel A Ollendorf et al.
Patricia G Synnott et al.
Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England States Consortium Systems Organization, Blue Cross Blue Sh...
Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy [0.03%]
利福昔明治疗肝性脑病患者的 cost-effectiveness 分析
Arun B Jesudian,Maliha Ahmad,Duygu Bozkaya et al.
Arun B Jesudian et al.
Background: Hepatic encephalopathy (HE) is a complication of cirrhosis of the liver causing neuropsychiatric abnormalities. Clinical manifestations of overt HE result in increased health care resource utilization and effe...
Editor's Note [0.03%]
编者按
Laura E Happe
Laura E Happe
John B Watkins,Sean D Sullivan,Elizabeth Sampsel et al.
John B Watkins et al.
No funding was required for this project. The authors are or have been members of the Format Executive Committee.
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015 [0.03%]
2010至2015年美国非机羣机构化成年人口患多发性硬化症的边际医疗保健支出负担
Jagadeswara Rao Earla,J Douglas Thornton,George J Hutton et al.
Jagadeswara Rao Earla et al.
Background: Multiple sclerosis (MS) is a chronic neuroinflammatory disorder with significant health care burden. However, little is known about health care expenditures since the introduction of oral agents for MS after 2...
Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers [0.03%]
心血管疾病的附加疗法：审议ICER的报告及对支付方潜在影响的回顾性分析
Jonathan W Magness,Caitlin Arnwine,Kelsey Lockwood et al.
Jonathan W Magness et al.
No outside funding supported this commentary. The authors have nothing to disclose.
Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control [0.03%]
丙型肝炎病毒的治疗及其对长期血糖控制的影响
Jennifer Andres,Michael Barros,Michael Arutunian et al.
Jennifer Andres et al.
Background: Chronic hepatitis C virus (HCV) infection has been linked to worsening glycemic control in patients with diabetes due to insulin resistance. Studies have shown that treating HCV improves glycemic control in th...